Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy
Science Advances · 12.09.2025 · 11 (37)
DOI: 10.1126/sciadv.adx8134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 12.09.2025. Verfasst von Jielin Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PTDSS1 (phosphatidylserine synthase 1) encodes an enzyme that facilitates production of phosphatidylserine (PS), which mediates a global immunosuppressive signal. Here, based on in vivo CRISPR screen, we identified PTDSS1 as a target to improve anti–PD-1 therapy. Depletion of Ptdss1 in tumor cells increased expression of interferon-γ (IFN-γ)–regulated genes, including B2m , Cxcl9 , Cxcl10 , and Stat1 , even in the absence of IFN-γ stimulation in vitro. Loss of Ptdss1 in tumor cells also led to increased expression of MHC-I, enhanced cytotoxicity of CD8 + T cells, and increased frequency of an iNOS + myeloid subset. A gene signature derived from the iNOS + myeloid cell subset correlated with clinical benefit in patients treated with anti–PD-1 therapy. Moreover, genetic and pharmacological inhibition of Ptdss1 in different tumor models improved anti–PD-1 therapy. Together, our results provide insights on a therapeutic strategy for overcoming immunosuppression by inhibiting PTDSS1 and provide rationale for development of a combination immunotherapy strategy composed of PTDSS1 inhibition plus PD-1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Graduate School of Biomedical Sciences, University of Texas MD Anderson UTHealth Houston, Houston, TX 77030, USA.
- James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Independent Researcher, San Francisco, California, USA.
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Jielin Liu, Shelley Herbrich, Sreyashi Basu, Yulong Chen, Swetha Anandhan, Sangeeta Goswami, Padmanee Sharma
Förderung
- NCI NIH HHS
Zitieren
APA
Liu, J., Herbrich, S., Basu, S., Chen, Y., Nagarajan, A., Anandhan, S., Goswami, S., Xiong, L., Guan, B., & Sharma, P. (2025). Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy. Science Advances, 11(37). https://doi.org/10.1126/sciadv.adx8134
Vancouver
Liu J, Herbrich S, Basu S, Chen Y, Nagarajan A, Anandhan S, et al. Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy. Science Advances. 2025;11(37). doi:10.1126/sciadv.adx8134
BibTeX
@article{Liu2025,
author = {Liu, Jielin and Herbrich, Shelley and Basu, Sreyashi and Chen, Yulong and Nagarajan, Ashwat and Anandhan, Swetha and Goswami, Sangeeta and Xiong, Liangwen and Guan, Baoxiang and Sharma, Padmanee},
title = {Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {37},
doi = {10.1126/sciadv.adx8134}
}
EUVIMED